CoChat

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

Open access
Yuan, Xi, Tang, Zhiyu, Du, Rong, Yao, Zhan, Cheung, Shing‐Hu, Zhang, Xinwen, Wei, Jing, Zhao, Yuan, Du, Yunguang, Liu, Ye, Hu, Xiaoxia, Gong, Wenfeng, Liu, Yong, Gao, Yajuan, Huang, Zhiyue, Cao, Zongfu, Wei, Min, Zhou, Changyou, Wang, Lai, Rosen, Neal, Smith, Paul D., Luo, Lusong · 2020 · Molecular Oncology
Cited by 39

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The mutation of K‐RAS represents one of the most frequent genetic alterations in cancer. Targeting of downstream effectors of RAS, including of MEK and ERK, has limited clinical success in cancer patients with K‐RAS mutations. The reduced sensitivity of K‐RAS‐mutated cells to certain MEK inhibitors (MEKi) is associated with the feedback phosphorylation of MEK by C‐RAF and with the reactivation of mitogen‐activated protein kinase (MAPK) signaling. Here, we report that the RAF dimer inhibitors lifirafenib (BGB‐283) and compound C show a strong synergistic effect with MEKi, including mirdametinib (PD‐0325901) and selumetinib, in suppressing the proliferation of K‐RAS‐mutated non‐small‐cell lung cancer and colorectal cancer (CRC) cell lines. This synergistic effect was not observed with the B‐RAF V600E selective inhibitor vemurafenib. Our mechanistic analysis revealed that RAF dimer inhibition suppresses RAF‐dependent MEK reactivation and leads to the sustained inhibition of MAPK signaling in K‐RAS‐mutated cells. This synergistic effect was also observed in several K‐RAS mutant mouse xenograft models. A pharmacodynamic analysis supported a role for the synergistic phospho‐ERK blockade in enhancing the antitumor activity observed in the K‐RAS mutant models. These findings support a vertical inhibition strategy in which RAF dimer and MEKi are combined to target K‐RAS‐mutated cancers, and have led to a Phase 1b/2 combination therapy study of lifirafenib and mirdametinib in solid tumor patients with K‐RAS mutations and other MAPK pathway aberrations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/1878-0261.12698

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 39

Metadata

Authors
Yuan, X., Tang, Z., Du, R., Yao, Z., Cheung, S., Zhang, X., Wei, J., Zhao, Y., Du, Y., Liu, Y., Hu, X., Gong, W., Liu, Y., Gao, Y., Huang, Z., Cao, Z., Wei, M., Zhou, C., Wang, L., Rosen, N., Smith, P. D., & Luo, L.
Venue
Molecular Oncology
Publisher
Wiley
Published
2020-05-18
Volume
14
Issue
8
Pages
1833-1849
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W3019373524
Cited by
39
References
14
FWCI
1.45
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors. https://app.cochat.ai/papers/10.1002/1878-0261.12698
The paper
Yuan, X., Tang, Z., Du, R., Yao, Z., Cheung, S., Zhang, X., Wei, J., Zhao, Y., Du, Y., Liu, Y., Hu, X., Gong, W., Liu, Y., Gao, Y., Huang, Z., Cao, Z., Wei, M., Zhou, C., Wang, L., . . . Luo, L. (2020). RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors. Molecular Oncology. https://doi.org/10.1002/1878-0261.12698

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.